Alex Philippidis Senior News Editor Genetic Engineering & Biotechnology News

To these victors go the most shares of biopharma stock.

CEOs and other executives and relatives with the biggest stakes in biopharma drug development and tools companies saw those stakes grow in value along with the market last year, judging from this year’s GEN List of what we call “molecular millionaires.”

More often than not, the healthiest growth over the past year has been enjoyed by those invested in biotech giants with new products approved and/or launched to market in 2013—not only now-familiar drug developers like Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Celgene, but tools companies such as Illumina and BD (Becton, Dickinson & Co.).

And in a sign of how biopharma is being reshaped by fast-growing, deal-driven companies, the second-ranked “molecular millionaire” this year was the chief executive of a company that was nowhere near the top of past Lists, but is intent on becoming a top-five biopharma in terms of market capitalization by the end of 2016.

Big pharma continues to command only a small presence on this List, with only four executives from three companies appearing. Ranking highest among big pharmas, at No. 14, was not a current pharma exec but a retired chairman. CEOs and other top executives from several other pharma giants missed the top 25, including Pfizer, Johnson & Johnson, and Eli Lilly.

Following is an updated List of 25 executives of publicly traded biopharma drug developers and tools/technology companies, ranked by the total value of their shares of common stock as stated on the companies’ proxy statements or Form 20-F statements. Each executive is listed with their title and company, the total value of their shares of common stock, the number of shares of common stock (by category where available), and the closing share price of their company’s stock as of the “record date” for determining shareholders entitled to notice of, and to vote at, their company’s annual meeting, with footnotes where applicable.

This year’s List is reduced from last year’s top 40, reflecting both a desire to zero in on top investors and a narrowing of criteria for inclusion to stakeholders whose companies derive at least a majority of their revenues from biopharma tools—and a consequent removal of companies where biopharma tool operations constituted a minority percentage of activity in 2013.


#25. Vincent A. Forlenza

Chairman, CEO, and President, BD (Becton, Dickinson & Co.)

Total value of all shares: $98,886,832

910,644 shares of common stock as of December 1, 20131

Closing price as of December 1, 2013: $108.592


#24. Robert A. Bradway

Chairman and CEO, Amgen

Total value of all shares: $104,465,1343

481,306 shares of common stock and 362,107 shares acquirable within 60 days of March 174

Closing price on March 17: $123.86


#23. Kenneth C. Frazier

Chairman and CEO, Merck & Co.

Total value of all shares: $115,201,9235

311,110 shares of common stock6 and 1,710,331 in options/stock units that were exercisable/distributable within 60 days as of February 28

Closing price on February 28: $56.99


#22. James M. Cornelius

Nonexecutive Chairman, Bristol-Myers Squibb7

Total value of all shares: $132,488,8878

1,335,908 total shares of common stock;9 1,035,000 shares underlying options or stock units10 as of March 12; and 27,515 common shares underlying deferred share units11

Closing price as of March 12: $55.24


#21. Robert J. Hugin

Chairman and CEO, Celgene

Total value of all shares: $148,514,800

2,065,000 shares of common stock as of April 2112

Closing price on April 21: $71.92


#20. Jean-Jacques Bienaimé

CEO, BioMarin Pharmaceutical

Total value of all shares: $154,439,795

1,996,636 shares of common stock as of March 1513

Closing price as of March 15: $77.3514


#19. Robert F. Spoerry

Chairman, Mettler Toledo International15

Total value of all shares: $154,682,49616

370,190 direct shares of common stock and 262,510 indirect shares of common stock subject to stock options that are exercisable within 60 days, as of March 1017

Closing price on March 10: $244.48


#18. Olivier T. Filliol

President and CEO, Mettler Toledo International

Total value of all shares: $162,146,22618

16,279 direct shares of common stock and 646,950 indirect shares of common stock subject to stock options that were exercisable within 60 days, as of March 10

Closing price on March 10: $244.48


#17. Seamus Mulligan

Director, Jazz Pharmaceuticals19

Total value of all shares: $185,957,496

1,461,930 shares of common stock owned as of May 1520

Closing price on May 15: $127.20


#16. Joshua Boger, Ph.D.

Founder and Director, Vertex Pharmaceuticals21

Total value of all shares: $192,304,491

2,414,369 shares of common stock as of March 1022

Closing price on March 10: $79.65


#15. Lamberto Andreotti

CEO, Bristol-Myers Squibb

Total value of shares of common stock: $196,109,12623

2,099,304 total shares of common stock24 and 1,450,825 shares underlying options or stock units25 as of March 12

Closing price as of March 12: $55.24


#14. Robert L. Parkinson, Jr.

Chairman and CEO, Baxter International

Total value of all shares: $200,390,21926

462,027 shares of common stock; 2,471,944 shares that include options that were exercisable as of February 1, and options that became exercisable within 60 days thereafter

Closing price: $68.30 as of February 127


#13. Jay T. Flatley

CEO, Illumina

Total value of all shares: $276,317,804

1,772,859 total shares of common stock as of April 128

Closing price on April 1: $155.86 


#12. David E.I. Pyott

Chairman and CEO, Allergan

Total value of all shares: $342,504,50629

2,664,368 shares of common stock as of March 1130

Closing price on March 11: $128.55


#11. Martine Rothblatt, Ph.D., J.D., M.B.A.

Chairman and CEO, United Therapeutics

Total value of all shares: $365,324,219

3,937,532 shares of common stock as of April 1131

Closing price on April 11: $92.78


#10. Leonard Bell, M.D.

CEO, Alexion Pharmaceuticals

Total value of all shares: $489,264,964

2,748,834 shares of common stock as of March 1732

Closing price on March 17: $177.99


#9. Phillip Frost, M.D.

Chairman, Teva Pharmaceutical Industries

Total value of all shares: $577,932,919

14,419,484 shares as of December 31, 2013

Closing price on December 31, 2013: $40.08


#8. Steven Schwartz

Shareholder, Bio-Rad Laboratories33

Total value of all shares: $581,628,60234

364,494 Class A shares of common stock35 and 4,076,436 Class B shares of common stock36 as of February 27

Closing price on February 27: $130.97


#7. Norman Schwartz

Chairman, President, and CEO, Bio-Rad Laboratories37

Total value of all shares: $645,832,45338

411,252 Class A shares of common stock39 and 4,519,896 Class B shares of common stock40 as of February 27

Closing price on February 27: $130.97


#6. George D. Yancopoulos, M.D., Ph.D.

Founding Scientist, President, Regeneron Laboratories, and Chief Scientific Officer, Regeneron Pharmaceuticals

Total value of all shares: $769,337,02641

2,549,880 shares of common stock42 and 42,750 Class A shares as of April 1743

Closing price on April 17: $296.74


#5. P. Roy Vagelos, M.D.

Chairman, Regeneron Pharmaceuticals

Total value of all shares: $874,021,260

2,945,411 shares of common stock as of April 1744

Closing price on April 17: $296.74 


#4. John C. Martin, Ph.D.

Chairman and CEO, Gilead Sciences

Total value of all shares: $964,856,185

11,654,260 shares of common stock as of February 2845

Closing price on February 28: $82.79


#3. Alice N. Schwartz

Co-founder and Director, Bio-Rad Laboratories

Total value of all shares: $970,065,06046

2,807,223 Class A shares of common stock47 and 4,599,550 Class B shares of common stock48 as of February 27

Closing price on February 27: $130.97


#2. J. Michael Pearson

Chairman and CEO, Valeant Pharmaceutical Industries

Total value of all shares: $1,397,432,671

10,600,263 shares of common stock as of March 3149,50

Closing price on March 31: $131.83


#1. Leonard S. Schleifer, M.D., Ph.D.

Founder, President and CEO, Regeneron Pharmaceuticals

Total value of all shares: $1,577,837,20451

3,589,173 shares of common stock52 and 1,728,065 Class A shares53,54 as of April 17

Closing price on April 17: $296.74

















Notes:
1 Includes 831,444 shares under outstanding stock appreciation rights and restricted stock units that Mr. Forlenza may acquire within 60 days.
2 Share price reflects closing price on last trading day before December 1, 2013, which was November 29, 2013.
3 Includes $59,614,561 in shares of common stock and $44,850,573 in shares that were acquirable within 60 days of March 17.
4 Includes 18,597 shares he was eligible to acquire upon the vesting of restricted stock units and related dividend equivalents (excluding fractional shares), where the shares were issuable as of March 17, or within 60 days thereafter; as well as 343,510 stock options that were vested as of March 17, or within 60 days thereafter.
5 Includes $17,730,159 in shares of common stock and $97,471,764 in shares Frazier could have acquired through the exercise of outstanding stock options within 60 days of February 28
6 Includes equivalent shares of common stock held by the Trustee of the Merck U.S. Savings Plan, as applicable, as of January 8 for the accounts of Frazier (3,445 shares) and all directors and executive officers as a group (16,053 shares).
7 Served as Chairman and CEO from 2008–2010, and as CEO from 2006–2008.
8 Includes $73,795,558 in shares of common stock; $57,173,400 in shares underlying options or stock units; and $1,519,929 in common shares underlying deferred share units.
9 Consists of direct and indirect ownership of shares, shares credited to the accounts of the executive officers under the Bristol-Myers Squibb Company Savings and Investment Program, stock options that are currently exercisable or exercisable within 60 days, restricted stock units that vest within 60 days, the target number of market share units that vest within 60 days, and deferred share units.
10 Consists of shares underlying stock options that are currently exercisable or that will become exercisable within 60 days, restricted stock units that vest within 60 days, and the target number of market share units that vest within 60 days. None of these shares have any voting rights.
11 Consists of deferred share units that are valued according to the market value and shareholder return on equivalent shares of common stock. Deferred share units have no voting rights.
12 Consists of 524,879 shares of common stock, 1,475,200 shares of common Stock underlying stock options, 13,589 shares of common stock held in our 401(k) Plan for the benefit of Mr. Hugin, 46,532 shares of common stock held by a family foundation of which Mr. Hugin is a trustee, and 4,800 shares of common stock owned by Mr. Hugin’s children.
13 Includes 1,932,295 shares of common stock subject to options exercisable, as well as restricted stock units that will vest within 60 days following March 15. This number includes 60,000 options held in trusts for Mr. Bienaimé’s children.
14 Share price reflects closing price on last trading day before March 15, which was March 14.
15 Served as President and CEO from 1993 to 2007; has been a Director since 1996 and Chairman since 1998.
16 Includes $90,504,051 in direct shares of common stock and $64,178,445 in indirect shares of common stock.
17 Includes 346,826 shares held by his children (with respect to which he retains a life interest, including full voting and dispositive control) and 17,777 shares held by his spouse. The shares are not categorized as direct or indirect. “Mr. Spoerry disclaims beneficial ownership for the shares held by his children and wife,” according to the company’s 2014 Proxy Statement.
18 Includes $3,979,890 in direct shares of common stock and $158,166,336 in indirect shares of common stock.
19 Mulligan served as Chief Business Officer, International Business Development from the company’s merger with Azur Pharma in 2012, when he joined Jazz Pharma’s board, until February 2013. Since then, he has served as Chairman and Chief Executive Officer of Adapt Pharma, a specialty pharmaceutical company, and since 2006, Mulligan has served as the Executive Chairman of Circ Pharma and its subsidiaries, a pharmaceutical development stage group.
20 Includes 8,625 ordinary shares he had the right to acquire pursuant to options exercisable within 60 days of May 15.
21 Served as CEO from 1992–2009, as Chairman from 1997–2006, and as President from the company’s inception in 1989 to 2000, and again from 2005–2009.
22 Includes 1,762,188 shares acquirable through options that were exercisable within 60 days after March 10; and unvested shares of restricted stock as of March 10.
23 Includes $115,965,553 in shares of common stock and $80,143,573 in shares underlying options or stock units.
24 Consists of direct and indirect ownership of shares, shares credited to the accounts of the executive officers under the Bristol-Myers Squibb Company Savings and Investment Program, stock options that are currently exercisable or exercisable within 60 days, restricted stock units that vest within 60 days, the target number of market share units that vest within 60 days and deferred share units.
25 Consists of shares underlying stock options that are currently exercisable or that will become exercisable within 60 days, restricted stock units that vest within 60 days and the target number of market share units that vest within 60 days. None of these shares have any voting rights.
26 Includes $31,556,444 in shares of common stock, and $168,833,775 in shares that include options that were exercisable as of February 1, and options that became exercisable within 60 days thereafter.
27 Share price reflects closing price on last trading day before February 1, which was January 31.
28 Includes 320,047 shares of common stock excluding stock options; and 1,452,812 shares that Include stock options that were exercisable as of April 1, and stock options that vested, or became exercisable, within 60 days of April 1.
29 Includes $30,102,296 in shares of common stock; rights to acquire an additional $291,191,460 in shares of common stock; and $21,210,750 in unvested shares of restricted stock/units.
30 234,168 shares of common stock; 2,265,200 shares which he had rights to acquire within 60 days of March 11, and 165,000 unvested shares of restricted stock/units.
31 Includes currently exercisable options to purchase 3,404,132 shares. Also includes 533,094 shares held indirectly by trust and 166 shares held by Dr. Rothblatt’s spouse.
32 Includes 2,027,658 shares of common stock that may be acquired upon the exercise of options that were exercisable within 60 days of March 17; and 255,374 shares held in various trusts of which Dr. Bell or his spouse is a trustee.
33 Son of company co-founder Alice N. Schwartz, ranked number three on this List.
34  Includes $47,737,779 in Class A shares of common stock and $533,890,823 in Class B shares of common stock that hold preferential voting rights, such as 10 times the voting power of Class As, and election of three directors (versus two for Class As), at the company’s Annual Meeting.
35 Includes 2,348 Class A shares owned by his wife, as to which he disclaims any beneficial ownership. Includes 37,825 Class A shares pledged as security.
36 Includes 4,060,054 shares of Class B common stock held by Blue Raven Partners, L.P., where he shares voting and dispositive power with Alice N. Schwartz and Norman Schwartz. Includes 12,371 Class B shares owned by Steven Schwartz’s wife, as to which he disclaims any beneficial ownership.
37 Son of company co-founder Alice N. Schwartz, ranked number three on this List.
38 Includes $53,861,674 in Class A shares of common stock and $591,970,779 in Class B shares of common stock that hold preferential voting rights, such as 10 times the voting power of Class As, and election of three directors (versus two for Class As), at the company’s Annual Meeting.
39 Includes 37,825 shares of Class A common stock pledged as security. He is among directors and officers who as a group have similar rights to acquire 84,389 Class A shares.
40 Includes 4,060,054 shares of Class B Common Stock held by Blue Raven Partners, L.P., where he shares voting and dispositive power with Alice N. Schwartz and Steven Schwartz. Includes rights to acquire 301,912 Class B shares immediately or within 60 days of February 27 under the Company’s employee stock purchase plan and stock option agreements. Includes 12,371 Class B shares owned by Norman Schwartz’s wife, as to which he disclaims any beneficial ownership. He is among directors and officers who as a group have similar rights to acquire 301,991 Class B shares.
41 Includes $756,651,391 in common stock and $12,685,635 in Class A shares
42 Includes 1,433,164 shares of common stock purchasable upon exercise of options granted pursuant to the Second Amended and Restated 2000 Long-Term Incentive Plan (or a predecessor version of the plan) which are exercisable or become so within 60 days after April 17; 500,000 shares of restricted stock which vest on December 17, 2017, and 5,623 shares of common stock held in an account under the company’s 401(k) savings plan. Also includes 568,343 shares of common stock held in trust for the benefit of Dr. Yancopoulos’s children and certain other family members, of which Dr. Yancopoulos is a trustee.
43 Includes 19,383 shares of Class A stock held in trust for the benefit of Dr. Yancopoulos’ children and certain other family members, of which Dr. Yancopoulos is a trustee.
44 Includes 2,200,996 shares of common stock purchasable upon exercise of options granted pursuant to the Second Amended and Restated 2000 Long-Term Incentive Plan (or a predecessor version of the plan), which were exercisable or became so within 60 days after April 17; and 2,270 shares of common stock held in an account under the company’s 401(k) savings plan. Includes 157,124 shares of common stock held in a charitable lead annuity trust, and 10,965 shares of common stock held in a separate grantor retained annuity trust, of which Dr. Vagelos is the trustee. Includes 103,275 shares of common stock held in a trust for his grandchildren, of which Dr. Vagelos’ wife is the trustee. Includes 1,203 shares of common stock held in trust for his grandchildren, of which Dr. Vagelos, his wife, or both Dr. Vagelos and his wife are trustees. Includes 33,199 shares of common stock held by the Marianthi Foundation and 295,540 shares of common stock held by the Pindaros Foundation (both are charitable foundations), of which Dr. Vagelos is a director and an officer. Dr. Vagelos disclaims beneficial ownership of the shares held by these charitable foundations.
45 Includes 7,596,171 shares subject to stock options that were exercisable within 60 days of February 28.
46 Includes $367,661,996 in Class A shares of common stock and $602,403,064 in Class B shares of common stock that hold preferential voting rights, such as 10 times the voting power of Class As and election of three directors, versus two for Class As, at the company’s Annual Meeting.
47 Includes 2,807,223 shares of Class A common stock, which are held in the following trusts, for which Alice N. Schwartz is the sole trustee: the David and Alice N. Schwartz Charitable Remainder Unitrust (34,311 shares); the David Schwartz Exemption Trust (90 shares); the David Schwartz Exempt Marital Trust (240 shares); the David Schwartz Non-Exempt Marital Trust (898,931 shares); and the Alice N. Schwartz Revocable Trust (1,873,651 shares). Of the Class A shares, 1,167,088 shares have been pledged as security.
48 Includes 4,060,054 shares of Class B Common Stock held by Blue Raven Partners, L.P., where she shares voting and dispositive power with Norman Schwartz and Steven Schwartz; and 498,320 shares of Class B common stock, which are held in the following trusts, for which Alice N. Schwartz is the sole trustee: the Alice N. Schwartz Revocable Trust (441,320 shares); and the David Schwartz Exemption Trust (57,000 shares). Also includes 41,176 Class B shares held by DANSA Partners Limited, a California limited partnership, of which Alice N. Schwartz is a general partner. Of the Class B shares, 41,176 shares have been pledged as security.
49 The amount reported includes 2,028,516 shares which were pledged in connection with loans used to fund tax and other obligations associated with vesting and delivery of equity incentive awards and purchases of company shares. The pledging of the shares was approved by the company’s board of directors.
50 Includes 4,319,659 shares subject to options that are currently exercisable, or were exercisable within 60 days after March 31; as well as 580,676 restricted stock units (RSUs) that vested and become deliverable February 1, 2019, but have not yet been released.
51 Includes $1,065,051,196 in common stock owned and $512,786,008 in Class A shares owned.
52 Includes 1,813,371 shares of common stock purchasable upon the exercise of options granted pursuant to the Second Amended and Restated 2000 Long-Term Incentive Plan (or a predecessor version of the plan) which were exercisable or became so within 60 days after April 17; and 5,650 shares of common stock held in an account under the company’s 401(k) Savings Plan.
53 Includes 17,275 shares of Class A stock held in trust for the benefit of Dr. Schleifer’s son, of which Dr. Schleifer is a trustee.
54 Class A stock is convertible on a share-for-share basis into common stock. The Class A stock is entitled to ten votes per share at the Annual Meeting, and the common stock is entitled to one vote per share.

This site uses Akismet to reduce spam. Learn how your comment data is processed.